Skip to main content

Advertisement

SpringerLink
Log in

Kidney Cancer Integrative Oncology: Possible Options for Care

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This study aims to review how complementary and integrative medicine (CIM), defined as therapies utilizing nutrition, physical activity, herbs, supplements, mind-body therapies, homeopathy, and other non-traditional therapies, can address the prevention, treatment, side effects, and recurrence of kidney cancer. This review discusses advances and discoveries in research, gaps in research, current debates on the subject, and directions for future research. We queried Ovid MEDLINE and PubMed databases using the search terms kidney cancer, integrative medicine, integrative oncology, nutrition, supplements, treatment, prevention, and therapy. Searches were limited to integrative medicine and integrative oncology. We reviewed CIM therapies related to prevention, treatment, side effect mitigation, and recurrence of kidney cancers.

Recent Findings

Search results yielded 211 studies, of which 87 were relevant to this review. Studies related to CIM and kidney cancer were clustered into themes, including nutrition, physical activity, supplements, mind-body therapies, and alternative therapies.

Summary

This review provides a foundation for utilizing the principles of integrative medicine in the prevention of and care for patients with kidney cancer and the need for further focused research on the effectiveness of CIM in kidney cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  PubMed  Google Scholar 

  2. Ridge CA, Pua BB, Madoff DC. Epidemiology and staging of renal cell carcinoma. Semin Intervent Radiol. 2014;31(1):3–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Gray RE, Harris GT. Renal cell carcinoma: diagnosis and management. Am Fam Physician. 2019;99(3):179–84.

    PubMed  Google Scholar 

  4. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502–10.

    Article  PubMed  Google Scholar 

  5. Hancock SB, Georgiades CS. Kidney cancer. Cancer J. 2016;22(6):387–92.

    Article  PubMed  Google Scholar 

  6. Kim SI, Kim SJ, Kim SJ, Cho DS. Prognostic nutritional index and prognosis in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol. 2021;39(10):623–30.

    Article  PubMed  Google Scholar 

  7. Tillery R, McGrady ME. Do complementary and integrative medicine therapies reduce healthcare utilization among oncology patients? A systematic review of the literature and recommendations. Eur J Oncol Nurs. 2018;36:1–8.

    Article  PubMed  Google Scholar 

  8. Liao Z, Fang Z, Gou S, Luo Y, Liu Y, He Z, et al. The role of diet in renal cell carcinoma incidence: an umbrella review of meta-analyses of observational studies. BMC Med. 2022;20(1):39.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rhee J, Loftfield E, Freedman ND, Liao LM, Sinha R, Purdue MP. Coffee consumption and risk of renal cell carcinoma in the NIH-AARP Diet and Health Study. Int J Epidemiol. 2021;50(5):1473–81.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Becalski A, Lau BPY, Lewis D, Seaman SW. Acrylamide in foods: occurrence, sources, and modeling. J Agric Food Chem. 2003;51(3):802–8.

    Article  PubMed  CAS  Google Scholar 

  11. Ikeda S, Sobue T, Kitamura T, Ishihara J, Kotemori A, Zha L, et al. Dietary acrylamide intake and the risks of renal cell, prostate, and bladder cancers: a Japan public health center-based prospective study. Nutrients. 2021;13(3)

  12. Jiang F, Teng M, Zhu Y-X, Li Y-J. No association between dietary acrylamide and renal cell carcinoma: an updated meta-analysis. J Sci Food Agric. 2020;100(7):3071–7.

    Article  PubMed  CAS  Google Scholar 

  13. Graff RE, Cho E, Preston MA, Sanchez A, Mucci LA, Wilson KM. Dietary acrylamide intake and risk of renal cell carcinoma in two large prospective cohorts. Cancer Epidemiol Biomarkers Prev. 2018;27(8):979–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Dalmartello M, Bravi F, Serraino D, Crispo A, Ferraroni M, La Vecchia C, et al. Dietary patterns in Italy and the risk of renal cell carcinoma. Nutrients. 2020;12(1)

  15. Xu X, Zhu Y, Li J, Wang S. Dietary fiber, glycemic index, glycemic load and renal cell carcinoma risk. Carcinogenesis. 2019;40(3):441–7.

    Article  PubMed  CAS  Google Scholar 

  16. Zhu J, Tu H, Matin SF, Tannir NM, Wood CG, Wu X. Glycemic index, glycemic load and carbohydrate intake in association with risk of renal cell carcinoma. Carcinogenesis. 2017;38(11):1129–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Zhang S, Jia Z, Yan Z, Yang J. Consumption of fruits and vegetables and risk of renal cell carcinoma: a meta-analysis of observational studies. Oncotarget. 2017;8(17):27892–903.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Deckers IAG, van den Brandt PA, van Engeland M, Soetekouw PMMB, Baldewijns MMLL, Goldbohm RA, et al. Long-term dietary sodium, potassium and fluid intake; exploring potential novel risk factors for renal cell cancer in the Netherlands Cohort Study on diet and cancer. Br J Cancer. 2014;110(3):797–801.

    Article  PubMed  CAS  Google Scholar 

  19. Lu D-L, Ren Z-J, Zhang Q, Ren P-W, Yang B, Liu L-R, et al. Meta-analysis of the association between the inflammatory potential of diet and urologic cancer risk. PloS One. 2018;13(10):e0204845.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Shivappa N, Blair CK, Prizment AE, Jacobs DR Jr, Hebert JR. Dietary inflammatory index and risk of renal cancer in the Iowa Women’s Health Study. Eur J Nutr. 2018;57(3):1207–13.

    Article  PubMed  Google Scholar 

  21. Shivappa N, Hebert JR, Rosato V, Rossi M, Montella M, Serraino D, et al. Dietary inflammatory index and renal cell carcinoma risk in an Italian case-control study. Nutr Cancer. 2017;69(6):833–9.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tahbaz R, Schmid M, Merseburger AS. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol. 2018;28(1):62–79.

    Article  PubMed  Google Scholar 

  23. Behrens G, Leitzmann MF. The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer. 2013;108(4):798–811.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Al-Bayati O, Hasan A, Pruthi D, Kaushik D, Liss MA. Systematic review of modifiable risk factors for kidney cancer. Urol Oncol. 2019;37(6):359–71.

    Article  PubMed  Google Scholar 

  25. Arthuso FZ, Courneya KS. Physical activity in patients with kidney cancer: a scoping review. Clin Genitourin Cancer. 2022;20(5):e369–e79.

    Article  PubMed  Google Scholar 

  26. Ho WJ, Simon MS, Yildiz VO, Shikany JM, Kato I, Beebe-Dimmer JL, et al. Antioxidant micronutrients and the risk of renal cell carcinoma in the Women’s Health Initiative cohort. Cancer. 2015;121(4):580–8.

    Article  PubMed  CAS  Google Scholar 

  27. Ferrere G, Tidjani Alou M, Liu P, Goubet A-G, Fidelle M, Kepp O, et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight. 2021;6(2)

  28. Fine EJ, Segal-Isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition. 2012;28(10):1028–35.

    Article  PubMed  CAS  Google Scholar 

  29. Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35(3):515–27.

    Article  PubMed  CAS  Google Scholar 

  30. Brown JC, Ligibel JA. The role of physical activity in oncology care. J Natl Cancer Inst Monogr. 2017;2017(52)

  31. World Cancer Research Fund, American Institute for Cancer Research. Diet, nutrition, physical activity and cancer: a global perspective. Continuous Update Project Exp Rep. 2018;

  32. Tabaczynski A, Courneya KS, Trinh L. Replacing sedentary time with physical activity and sleep: associations with quality of life in kidney cancer survivors. Cancer Causes Control. 2020;31(7):669–81.

    Article  PubMed  Google Scholar 

  33. Liss M, Natarajan L, Hasan A, Noguchi JL, White M, Parsons KJ. Physical activity decreases kidney cancer mortality. Curr Urol. 2017;10(4):193–8.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Haque I, Subramanian A, Huang C, Godwin A, Van Veldhuizen P, Banerjee S, et al. The role of compounds derived from natural supplement as anticancer agents in renal cell carcinoma: a review. Int J Mol Sci. 2017;19(1):107.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Khan N, Mukhtar H. Cancer and metastasis: prevention and treatment by green tea. Cancer Metastasis Rev. 2010;29(3):435–45.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Li G, Wang Z, Chong T, Yang J, Li H, Chen H. Curcumin enhances the radiosensitivity of renal cancer cells by suppressing NF-κB signaling pathway. Biomed Pharmacother. 2017;94:974–81.

    Article  PubMed  CAS  Google Scholar 

  37. Rutz J, Maxeiner S, Juengel E, Bernd A, Kippenberger S, Zöller N, et al. Growth and proliferation of renal cell carcinoma cells is blocked by low curcumin concentrations combined with visible light irradiation. Int J Mol Sci. 2019;20(6):1464.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Obaidi I, Cassidy H, Ibáñez Gaspar V, Mccaul J, Higgins M, Halász M, et al. Curcumin sensitizes kidney cancer cells to TRAIL-induced apoptosis via ROS mediated activation of JNK-CHOP pathway and upregulation of DR4. Biology. 2020;9(5):92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Obaidi I, Blanco Fernández A, Mcmorrow T. Curcumin sensitises cancerous kidney cells to TRAIL induced apoptosis via Let-7C mediated deregulation of cell cycle proteins and cellular metabolism. Int J Mol Sci. 2022;23(17):9569.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Gao R, Ma Y, Wang Y, Xu H. Curcumin inhibits the proliferation of renal cancer 786-O cells through MTOR signaling pathway and its mechanism. J Healthcare Eng. 2022;2022:1–7.

    CAS  Google Scholar 

  41. Den Hartogh DJ, Tsiani E. Health benefits of resveratrol in kidney disease: evidence from in vitro and in vivo studies. Nutrients. 2019;11(7):1624.

    Article  CAS  Google Scholar 

  42. Tian X, Zhang S, Zhang Q, Kang L, Ma C, Feng L, et al. Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma. J Nutr Biochem. 2020;85:108489.

    Article  PubMed  CAS  Google Scholar 

  43. Sun H, Zhang T, Liu R, Cao W, Zhang Z, Liu Z, et al. Resveratrol inhibition of renal cancer stem cell characteristics and modulation of the sonic hedgehog pathway. Nutr Cancer. 2021;73(7):1157–67.

    Article  PubMed  CAS  Google Scholar 

  44. Li J, Qiu M, Chen L, Liu L, Tan G, Liu J. Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism. Oncol Lett. 2017;13(2):613–20.

    Article  PubMed  CAS  Google Scholar 

  45. Min Z. Resveratrol enhances chemosensitivity of renal cell carcinoma to paclitaxel. Front Biosci. 2019;24(8):1452–61.

    Article  Google Scholar 

  46. Moreira M, Pobel C, Epaillard N, Simonaggio A, Oudard S, Vano Y-A. Resistance to cancer immunotherapy in metastatic renal cell carcinoma. Cancer Drug Resist. 2020;3:454–71.

    PubMed  PubMed Central  CAS  Google Scholar 

  47. Chen S, Wang Z, Huang Y, O'Barr SA, Wong RA, Yeung S, et al. Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review. Evid-Based Complementary Altern Med. 2014;2014:1–13.

    Google Scholar 

  48. Park JY, Choi P, Kim T, Ko H, Kim H-K, Kang KS, et al. Protective effects of processed ginseng and its active ginsenosides on cisplatin-induced nephrotoxicity: in vitro and in vivo studies. J Agric Food Chem. 2015;63(25):5964–9.

    Article  PubMed  CAS  Google Scholar 

  49. Jin D, Zhang Y, Duan L, Zhou R, Duan Y, Sun Y, et al. Panax ginseng C.A.Mey. as medicine: the potential use of Panax ginseng C.A.Mey. as a remedy for kidney protection from a pharmacological perspective. Front Pharmacol. 2021;12:734151.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Alpay M, Kismali G, Meral O, Sel T, Ozmerdivenli R, Pasin O. Antioxidant therapy impresses in oxidative stress-induced kidney cells. Bratisl Med J. 2017;118(02):89–94.

    Article  CAS  Google Scholar 

  51. Berkson BM, Calvo RF. The long-term survival of a patient with stage IV renal cell carcinoma following an integrative treatment approach including the intravenous α-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2018;17(3):986–93.

    Article  PubMed  Google Scholar 

  52. Ben-Eliyahu S, Yirmiya R, Liebeskind JC, Taylor AN, Gale RP. Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav Immun. 1991;5(2):193–205.

    Article  PubMed  CAS  Google Scholar 

  53. Rossman ML, Shrock D. Mind-body medicine in integrative cancer care. In: Abrams D, Weil A, editors. Integrative oncology. Oxford: Oxford University Press; 2014. p. 389–413.

    Google Scholar 

  54. MD Anderson Cancer Center. Integrative medicine center clinical services https://www.mdanderson.org/patients-family/diagnosis-treatment/care-centers-clinics/integrative-medicine-center/clinical-services.html. Accessed 30 Aug 2022

  55. Dana-Farber Cancer Institute. Leonard P. Zakim Center for Integrative Therapies and Healthy Living 2023 https://www.dana-farber.org/for-patients-and-families/care-and-treatment/support-services-and-amenities/zakim-center-for-integrative-therapies/. Accessed 30 Aug 2022

  56. Kastrati K, Mathies V, Kipp AP, Huebner J. Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow. J Patient Rep Outcomes. 2022;6(1):126.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Grégoire C, Faymonville ME, Vanhaudenhuyse A, Jerusalem G, Willems S, Bragard I. Randomized, controlled trial of an intervention combining self-care and self-hypnosis on fatigue, sleep, and emotional distress in posttreatment cancer patients: 1-year follow-up. Int J Clin Exp Hypn. 2022;70(2):136–55.

    Article  PubMed  Google Scholar 

  58. Osypiuk K, Ligibel J, Giobbie-Hurder A, Vergara-Diaz G, Bonato P, Quinn R, et al. Qigong mind-body exercise as a biopsychosocial therapy for persistent post-surgical pain in breast cancer: a pilot study. Integr Cancer Ther. 2020;19

  59. Kievisiene J, Jautakyte R, Rauckiene-Michaelsson A, Fatkulina N, Agostinis-Sobrinho C. The effect of art therapy and music therapy on breast cancer patients: what we know and what we need to find out - a systematic review. Evid-Based Complementary Altern Med. 2020;2020

  60. Simeit R, Deck R, Conta-Marx B. Sleep management training for cancer patients with insomnia. Support Care Cancer. 2004;12(3):176–83.

    Article  PubMed  Google Scholar 

  61. Daly WC, Han PKJ, Hayn M, Ryan ST, Hansen MH, Linscott JP, et al. Meditative and mind-body practice among patients with genitourinary malignancy. Urol Oncol. 2021;39(3):192 -e15.

    Article  PubMed  Google Scholar 

  62. Haier J, Duda A, Branss-Tallen C. Improvement of well-being in cancer patients by yoga training. Med J Indones. 2018;27(3):185–93.

    Article  Google Scholar 

  63. Mikolasek M, Witt CM, Barth J. Adherence to a mindfulness and relaxation self-care app for cancer patients: mixed-methods feasibility study. JMIR mHealth uHealth. 2018;6(12)

  64. Mikolasek M, Witt CM, Barth J. Effects and implementation of a mindfulness and relaxation app for patients with cancer: mixed methods feasibility study. JMIR. Cancer. 2021;7(1)

  65. Carlson LE, Zelinski E, Toivonen K, Flynn M, Qureshi M, Piedalue KA, et al. Mind-body therapies in cancer: what is the latest evidence? Curr Oncol Rep. 2017;19(10):67.

    Article  PubMed  Google Scholar 

  66. Frenkel M. Is there a role for homeopathy in cancer care? Questions and challenges. Curr Oncol Rep. 2015;17(9)

  67. Samuels N, Freed Y, Weitzen R, Ben-David M, Maimon Y, Eliyahu U, et al. Feasibility of homeopathic treatment for symptom reduction in an integrative oncology service. Integr Cancer Ther. 2018;17(2):486–92.

    Article  PubMed  Google Scholar 

  68. Lu W, Dean-Clower E, Doherty-Gilman A, Rosenthal DS. The value of acupuncture in cancer care. Hematol/Oncol Clin North Am. 2008;22(4):631–48.

    Article  PubMed  Google Scholar 

  69. Jang A, Brown C, Lamoury G, Morgia M, Boyle F, Marr I, et al. The effects of acupuncture on cancer-related fatigue: updated systematic review and meta-analysis. Integr Cancer Ther. 2020;19:153473542094967.

    Article  Google Scholar 

  70. Frączek P, Kilian-Kita A, Püsküllüoglu M, Krzemieniecki K. Acupuncture as anticancer treatment? Współczesna Onkologia. 2016;6:453–7.

    Article  Google Scholar 

  71. Trinh L, Plotnikoff RC, Rhodes RE, North S, Courneya KS. Physical activity preferences in a population-based sample of kidney cancer survivors. Support Care Cancer. 2012;20(8):1709–17.

    Article  PubMed  Google Scholar 

  72. Trinh L, Strom DA, Wong JN, Courneya KS. Modality-specific exercise guidelines and quality of life in kidney cancer survivors: a cross-sectional study. Psycho-Oncol. 2018;27(10):2419–26.

    Article  Google Scholar 

  73. Rock CL, Thomson CA, Sullivan KR, Howe CL, Kushi LH, Caan BJ, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. 2022;72(3):230–62.

    Article  PubMed  Google Scholar 

  74. Thomas R, Kenfield SA, Yanagisawa Y, Newton RU. Why exercise has a crucial role in cancer prevention, risk reduction and improved outcomes. Br Med Bull. 2021;139(1):100–19.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Filippini T, Malavolti M, Borrelli F, Izzo AA, Fairweather-Tait SJ, Horneber M, et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev. 2020;3(3):Cd005004.

    PubMed  Google Scholar 

  76. Shanmugam M, Rane G, Kanchi M, Arfuso F, Chinnathambi A, Zayed M, et al. The multifaceted role of curcumin in cancer prevention and treatment. Molecules. 2015;20(2):2728–69.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Xiang Y, Guo Z, Zhu P, Chen J, Huang Y. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med. 2019;8(5):1958–75.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Liu J, Wang S, Zhang Y, Fan H-T, Lin H-S. Traditional Chinese medicine and cancer: history, present situation, and development. Thoracic Cancer. 2015;6(5):561–9.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Zheng J, Xu W, Liu W, Tang H, Lu J, Yu K, et al. Traditional Chinese medicine Bu-Shen-Jian-Pi-Fang attenuates glycolysis and immune escape in clear cell renal cell carcinoma: results based on network pharmacology. Biosci Rep. 2021;41(6)

  80. Wang N, Feng Y, Cheung F, Wang X, Zhang Z, Feng Y. A Chinese medicine formula Gegen Qinlian decoction suppresses expansion of human renal carcinoma with inhibition of matrix metalloproteinase-2. Integr Cancer Ther. 2015;14(1):75–85.

    Article  PubMed  CAS  Google Scholar 

  81. Yang H-Y, Wang J-D, Lo T-C, Chen P-C. Increased mortality risk for cancers of the kidney and other urinary organs among Chinese herbalists. J Epidemiol. 2009;19(1):17–23.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Goyal S, Kubendran S, Kogan M, Rao YJ. High expectations: the landscape of clinical trials of medical marijuana in oncology. Complementary Ther Med. 2020;49(102336)

  83. Wilkie G, Sakr B, Rizack T. Medical marijuana use in oncology: a review. JAMA Oncol. 2016;2(5):670–5.

    Article  PubMed  Google Scholar 

  84. Grotenhermen F. Cannabis healing. Rochester, VT: Park Street Press; 2015.

    Google Scholar 

  85. Gandhi S, Vasisth G, Kapoor A. Systematic review of the potential role of cannabinoids as antiproliferative agents for urological cancers. Can Urol Assoc J. 2017;11(3-4):E138–e42.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Abrams DI, Guzman M. Can cannabis cure cancer? JAMA Onco. 2020;6:323–4.

    Article  Google Scholar 

  87. Abrams D, Weil A. Cannabinoids and cancer. In: Abrams D, Guzman M, editors. Integrative oncology. New York, NY: Oxford University Press; 2014. p. 246–84.

    Google Scholar 

  88. Benitez A, Yates TJ, Shamaldevi N, Bowen T, Lokeshwar VB. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. J Urol. 2013;190(1):285–90.

    Article  PubMed  CAS  Google Scholar 

  89. Kim C, Lee JH, Baek SH, Ko J-H, Nam D, Ahn KS. Korean red ginseng extract enhances the anticancer effects of sorafenib through abrogation of CREB and c-Jun activation in renal cell carcinoma. Phytother Res. 2017;31(7):1078–89.

    Article  PubMed  CAS  Google Scholar 

  90. Wu J, Yang N, Yuan M. Dietary and circulating vitamin D and risk of renal cell carcinoma: a meta-analysis of observational studies. International Braz J Urol. 2021;47(4):733–44.

    Article  PubMed  Google Scholar 

  91. Dizman N, Hsu J, Bergerot PG, Gillece JD, Folkerts M, Reining L, et al. Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma. Cancer Med. 2021;10(1):79–86.

    Article  PubMed  CAS  Google Scholar 

  92. Arora S, Aggarwal A, Singla P, Jyoti S, Tandon S. Anti-proliferative effects of homeopathic medicines on human kidney, colon and breast cancer cells. Homeopathy. 2013;102(4):274–82.

    Article  PubMed  Google Scholar 

  93. Arora S, Tandon C, Tandon S. Evaluation of the cytotoxic effects of CAM therapies: an in vitro study in normal kidney cell lines. Sci World J. 2014;2014:1–11.

    Google Scholar 

  94. Yun H, Sun L, Mao JJ. Growth of integrative medicine at leading cancer centers between 2009 and 2016: a systematic analysis of NCI-designated comprehensive cancer center websites. J Natl Cancer Inst Monogr. 2017;2017(52)

  95. Frenkel M, Sapire KJ, Lacey J, Zollman C, Sierpina VS. “What should I eat?”-addressing questions and challenges related to nutrition in the integrative oncology setting. Curr Oncol Rep. 2022;

  96. Kogan M, Liebmann-Smith J. Medical marijuana. New York, NY: Avery, Penguin, Random House; 2021. p. 164–88.

    Google Scholar 

  97. Abrams DI. Cannabis, cannabinoids and cannabis-based medicines in cancer care. Integ Cancer Therapies. 2022;21:1–11.

    Article  Google Scholar 

  98. Knoerl R, Phillips CS, Berfield J, Woods H, Acosta M, Tanasijevic A, et al. Lessons learned from the delivery of virtual integrative oncology interventions in clinical practice and research during the COVID-19 pandemic. Support Care Cancer. 2021;29(8):4191–4.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge Christen Walcher for editing and formatting the manuscript.

Author information

Authors and Affiliations

  1. Department of Family Medicine, University of Texas Medical Branch, 301 University Blvd, Rt. 1123, Galveston, TX, 77555-1123, USA

    Samuel Mathis & Victor S. Sierpina

Authors
  1. Samuel Mathis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor S. Sierpina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel Mathis.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mathis, S., Sierpina, V.S. Kidney Cancer Integrative Oncology: Possible Options for Care. Curr Oncol Rep 25, 1071–1080 (2023). https://doi.org/10.1007/s11912-023-01437-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-023-01437-x

Keywords

Search

Navigation